Siga falls after mpox drug fails to meet main goal in study

SIGA Technologies

15/08/2024 13:53

** Shares of SIGA technologies  SIGA.O  fall 42.52% to $7
premarket   
    ** Majority of mpox patients in a trial for co's antiviral
drug tecovirimat in Democratic Republic of Congo did not recover
more quickly than those given placebo, which meant the drug
failed in the study's main goal, SIGA says    
    ** The drug helped the very sickest mpox patients recover
more quickly than those given placebo, co says
    ** Tecovirimat helped those treated within seven days or
with severe disease – classed as having 100 or more skin lesions
– make "meaningful improvement"
    ** Mpox, a viral infection, was declared an emergency this
week by the World Health Organization after it spread from
Democratic Republic of Congo to neighboring countries
    ** Up to previous close, stock has more than doubled YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))